Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
ForSight VISION5
company
About
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $15M
- Industries
- Health Care,Incubators,Medical,Pharmaceutical
- Founded date
- Jan 1, 2010
- Number Of Employee
- 11 - 50
- Operating Status
- Active
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$23M
ForSight VISION5 has raised a total of
$23M
in funding over 2 rounds. Their latest funding was raised on
Apr 16, 2014 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 16, 2014 | Series C | $15M | 1 | — | — | Detail |
| Aug 22, 2012 | Series Unknown | $8M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
ForSight VISION5 is funded by 1 investors.
Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Versant Ventures
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
